Muscular Atrophy News and Research

RSS

Couples with infertility and miscarriages offered detailed embryo screening with 99% accuracy

Termed “preimplantation genetic screening (PGS)” the process involves a full chromosome count of embryos to ensure only the healthiest are implanted. It has a 99 per cent accuracy rate, giving hopeful parents the best chance to conceive and carry a healthy baby to term.

30 Apr 2012

Positive results from Repligen's RG3039 Phase 1 study for spinal muscular atrophy

Repligen Corporation today announced positive results from a Phase 1 study to evaluate the pharmacokinetic (PK) and safety profile of RG3039, a novel small molecule drug candidate for the potential treatment of spinal muscular atrophy (SMA).

25 Apr 2012

Huntington’s disease may protect against cancer: Study

Dr Jianguang Ji, Lund University, and Skåne University Hospital, Malmö, Sweden, and colleagues investigated data from the Swedish Cancer Registry. Researchers analyzed Swedish hospital data from 1969 to 2008. They found 1,510 patients with Huntington's disease. During the study period, 91 of those patients subsequently developed cancer. The authors said that was 53% lower than the levels expected for the general population.

15 Apr 2012

Abnormally low level of SMN protein linked to movement problems in spinal muscular atrophy

An abnormally low level of a protein in certain nerve cells is linked to movement problems that characterize the deadly childhood disorder spinal muscular atrophy, new research in animals suggests.

12 Apr 2012

Repligen total revenue increases to $7,165,000 for quarter ended December 31, 2011

Repligen Corporation today reported financial results for the quarter and nine-month fiscal year ended December 31, 2011.

17 Mar 2012

Drug companies forge joint ventures for smart pills

Imagine a "smart pill" containing a biodegradable electronic chip that monitors how your body responds to the medicine, broadcasts the information to your iPhone, which then emails the information to your physician.

16 Feb 2012

Biogen Idec 2011 total revenues increase 7% to $5.0 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its full year and fourth quarter 2011 results.

1 Feb 2012

Pediatric research project to expand data collection linked to newborn screening results

Within the first days of life, screening tests are performed on all newborns born in the U.S. to identify rare and often life-threatening medical conditions that are not apparent at birth. These newborn screening programs have been operating for decades, permitting doctors to intervene early and improve outcomes in potentially devastating conditions.

18 Jan 2012

One year and no recorded polio cases in India

The World Health Organization (WHO) reports that India has recorded no cases of polio for one full year - a significant benchmark for the South Asian nation and an encouraging development for health professionals fighting to eradicate the stubborn disease worldwide.

15 Jan 2012

BioTime to market muscle progenitor cell lines bearing hereditary diseases

BioTime, Inc. today announced that it has elected to market progenitors of muscle stem cells bearing hereditary diseases. BioTime will produce the products from five human embryonic stem (hES) cell lines from Reproductive Genetics Institute (RGI) of Chicago, Illinois.

4 Jan 2012

Einstein, Montefiore receive NINDS grant to establish clinical site for NeuroNEXT

In a development that could pave the way for treatment for rare neurological diseases and clues to more common ones, physician-scientists at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center, the University Hospital for Einstein, have secured a grant to establish a clinical site for the Network for Excellence in Neuroscience Clinical Trials.

2 Dec 2011

PTC, Roche announce licensing agreement for SMA programme

Roche, PTC Therapeutics, Inc. and the SMA Foundation, announced today a licensing agreement for PTC's Spinal Muscular Atrophy (SMA) programme.

30 Nov 2011

Targeting synthetic RNA to specific gene could help reduce severity of SMA

A team of University of Missouri researchers have found that targeting a synthetic molecule to a specific gene could help the severity of the disease Spinal Muscular Atrophy (SMA) - the leading genetic cause of infantile death in the world.

22 Nov 2011

SNI receives NINDS grant to conduct clinical research studies on brain disorders

Swedish Neuroscience Institute (SNI) has been selected by the National Institutes of Health as the Pacific Northwest member of a national consortium of 25 neuroscience centers that will conduct clinical research studies on a variety of brain-related diseases.

10 Nov 2011

Sex of patient plays a relevant role in recovery from facial paralysis

Research work drawn up by specialists from the Department of Plastic, Reconstructive and Aesthetic Surgery at the University of Navarra Hospital has shown that, after surgical treatment for facial paralysis through using muscular transplant and nervous transposition (connection of facial muscle to a nerve different from the injured facial nerve), the brain of a woman - in comparison to that of a male - manages to adapt itself better, recovers the spontaneous smile and has a greater time period available for repairing the paralysis.

9 Nov 2011

Cancer cells maintain rapid proliferation due to PK-M2 enzyme

Cancer cells maintain their life-style of extremely rapid growth and proliferation thanks to an enzyme called PK-M2 (pyruvate kinase M2) that alters the cells' ability to metabolize glucose - a phenomenon known as the Warburg effect.

3 Nov 2011

Communication breakdown between nerves and muscles in SMA mouse model

Researchers at the University of Missouri have identified a communication breakdown between nerves and muscles in mice that may provide new insight into the debilitating and fatal human disease known as spinal muscular atrophy.

27 Sep 2011

Cedars-Sinai inaugurates new facility to generate induced pluripotent stem cells

The Cedars-Sinai Regenerative Medicine Institute has opened a new Induced Pluripotent Stem Cell (iPSC) Core Facility to produce powerful cells capable of making all tissues of the body from adult human skin cells.

23 Sep 2011

New cell type could play an important role in spinal cord injury and disease

The Allen Institute for Brain Science announced today the discovery of a new class of cells in the spinal cord that act like neural stem cells, offering a fresh avenue in the search for therapies to treat spinal cord injury and disease.

16 Sep 2011

Walgreens, MDA team up to offer free seasonal flu shots

Nobody likes to get stuck with a needle. But influenza - the flu - is particularly hazardous for those with neuromuscular disease, which is why the Muscular Dystrophy Association (MDA) and Walgreens have teamed up once again to offer free seasonal flu shots now underway for people who have muscular dystrophy and related diseases.

14 Sep 2011